

1. **Beckwith CG**, Kurth AE, Bazerman LB, Patry EJ, Cates A, Tran L, **Noska A**, Kuo I. A pilot study of rapid hepatitis C virus testing in the Rhode Island Department of Corrections. *J Public Health*. 2016; 38 (1): 130-7. PMID: 25736438.
2. Ripp K, Orellana V, Dugdale C, Doberstein C, **Beckwith C**. The masquerading cyst: extraparenchymal neurocysticercosis presenting as acute meningitis. *Am J Med*. 2016; 129 (3): e1-3. PMID: 26477948.
3. Clifford GD, Silva I, Moody B, Li Q, Kella D, **Chahin A**, Kooistra T, Perry D, Mark RG. False alarm reduction in critical care. *Physiol Meas*. 2016 Aug;37(8):E5-E23. doi: 10.1088/0967-3334/37/8/E5. Epub 2016 Jul 25. PMID: 27454172
4. Glavis-Bloom J, Vasher S, Marmor M, Fine AB, **Chan PA**, **Tashima KT**, **Lonks JR**, Kojic EM. Candida and cardiovascular implantable electronic devices: a case of lead and native aortic valve endocarditis and literature review. *Mycoses*. 2015 Nov;58(11):637-41. doi: 10.1111/myc.12391. Epub 2015 Sep 25. Review. PMID: 26403965
5. Parker S, **Chan PA**, Oldenburg CE, Hoffmann M, Poceta J, Harvey J, Santamaria EK, Patel R, Sabatino KI, Nunn A. "Patient experiences of men who have sex with men using pre-exposure prophylaxis to prevent HIV infection." *AIDS Patient Care STDS*. 2015;Dec;29(12):639-42.
6. **Chan PA**, Rose J, Maher J, Benben S, Pfeiffer K, Almonte A, Poceta J, Marshall BD, **Lally M**, Nunn AS. A Latent Class Analysis of Risk Factors for Acquiring HIV Among Men Who Have Sex with Men: Implications for Implementing Pre-Exposure Prophylaxis Programs. *AIDS Patient Care STDS*. 29(11):597-605, 2015. PMID26389735 PMC4638212
7. **Chan PA**, A Huang, AK DeLong, JW Hogan, M Salemi, **R Kantor**. Phylogenetic investigation of a statewide HIV-1 epidemic reveals ongoing and active transmission networks among men who have sex with men. *Journal of AIDS*. 2015;70:428-435. PMID: 26258569.
8. Montgomery MC, Oldenburg CE, Nunn AS, Mena L, Anderson P, Liegler T, Mayer KH, Patel R, Almonte A, **Chan PA**. "Adherence to Pre-Exposure Prophylaxis for HIV Prevention in a Clinical Setting." *PLoS One*. 2016 Jun 22;11(6):e0157742.
9. Brinkley-Rubinstein L, Parker S, Gjelsvik A, Mena L, **Chan PA**, Harvey J, Marshall B, **Beckwith CG**, Rose J, Riggins R, Arnold T, Nunn A. "Condom use and incarceration among STI clinic attendees in the Deep South.: *BMC Public Health*. 2016 Sep 13;16:971.
10. **Chan PA**, Mena L, Patel R, Oldenburg CE, Beauchamps L, Perez-Brumer AG, Parker S, Mayer KH, Mimiaga MJ, Nunn A. "Retention in care outcomes for HIV pre-exposure prophylaxis implementation programmes among men who have sex with men in three US cities." *J Int AIDS Soc*. 2016 Jun 13;19(1):20903.

11. **Chan PA**, Robinette A, Montgomery M, Almonte A, **Cu-Uvin S**, **Lonks JR**, Chapin KCC, Kojic EM, and **Hardy EJ**. “Extragenital Infections Caused by Chlamydia trachomatis and Neisseria gonorrhoeae: A Review of the Literature.” *Infect Dis Obstet Gynecol*. 2016;2016:5758387. doi: 10.1155/2016/5758387. Review. PMID: 27366021
12. Merchant RC, Corner D, Garza E, Guan W, Mayer KH, Brown L, **Chan PA**. “Preferences for HIV pre-exposure prophylaxis (PrEP) information among men-who-have-sex-with-men (MSM) at community outreach settings.” *J Gay Lesbian Ment Health*. 2016;20(1):21-33.
13. Vigneswaran HT, Baird G, Hwang K, Renzulli J, **Chan PA**. “Etiology of symptomatic urethritis in men and association with sexual behaviors.” *RI Med J*. 2016. June 1;99(6):37-40.
14. CE Oldenburg, B Le, HT Huyen, DD Thien, NH Quan, KB Biello, A Nunn, **Chan PA**, KH Mayer, MJ Mimiaga, D Colby. “Antiretroviral pre-exposure prophylaxis preferences among men who have sex with men in Vietnam: Results from a nationwide survey.” *Sex Health*. 2016 Jul 22. doi: 10.1071/SH15144. PMID: 27444753
15. **Chan PA**, Towey C, Poceta J, Rose J, Bertrand T, **Kantor R**, Harvey J, Santamaria EK, Alexander-Scott N, and Nunn A. “Online Hookup Sites for Meeting Sexual Partners Among Men Who Have Sex with Men in Rhode Island, 2013: A Call for Public Health Action.” *Public Health Reports*. 2016; 131(2): 264-271.
16. Nunn A, Towey C, **Chan PA**, Parker S, Nichols E, Oleskey P, Yolken A, Harvey J, Banerjee G, Stopka T, Trosskin S. “Routine HIV screening in an urban community health center: Results from a geographically focused implementation science program.” *Public Health Reports*. 2016;131 Suppl 1:30-40.
17. Marshall BD, Perez-Brumer AG, MacCarthy S, Mena L, **Chan PA**, Towey C, Barnett N, Parker S, Barnes A, Brinkley-Rubinstein L, Rose JS, Nunn AS. “Individual and partner-level factors associated with condom non-use among African American STI clinic attendees in the Deep South: An event-level analysis.” *AIDS and Behavior*. 2016;20(6):1334-1342.
18. K Brooks, A DeLong, M Balamane, L Schreier, M Orido, E Kemboi, M Chepkenja, E Kemboi, M D’Antuono, **Chan PA**, W Emonyi, L Diero, **Coetzer M**, **R Kantor**. HemaSpot™, a Novel Blood Storage Device for HIV Drug Resistance Testing. *J Clin Microbiol*. 2016;54:223-5. PMID 26560534.
19. K Brooks, L Diero, A Delong, M Balamane, M Reitsma, E Kemboi, M Orido, **Coetzer M**, J Hogan, **Kantor R**. Treatment failure and drug resistance in HIV-positive Patients on Tenofovir-Based First-Line Antiretroviral Therapy in western Kenya. *J Int AIDS Soc*. 2016;19:20798. PMCID: PMC4882399.

20. **Cunha CB**, Kassakian SZ, Chan R, Tenover F, Ziakis P, Chapin KC, **Mermel LA**. Incidence and Risk Factors for Colonization with Carbapenem-Resistant Bacteria Among Nursing Home Residents Admitted to Acute Care Hospitals. *Am J Infect Control*. 44:126-30, 2016.
21. Hudepohl NJ, **Cunha CB**, **Mermel LA**. Antibiotic Prescribing for Urinary Tract Infections in the Emergency Department Based on Local Antibiotic Resistance Patterns: Implications for Antimicrobial Stewardship. *Infect Control Hosp Epidemiology*. 37:359-60, 2016.
22. **Cunha CB**. Severe Adenovirus Pneumonia: Diagnostic Accuracy of Viral Respiratory PCR is Related to Specimen Number as well as Source: Antimicrobial Stewardship Implications. *Infect Control Hosp Epidemiology*. 37:1127-1129, 2016.
23. **Cunha CB**, **D'Agata EMC**. Implementing an Antimicrobial Stewardship Program in Out-Patient Dialysis Units. *Curr Opin Nephrol Hypertens*, Epub ahead of print, 2016.
24. Rhodes CM, **Cu-Uvin S**, **Rana AI**. Pregnancy Desire, Partner Serodiscordance, and Partner HIV Disclosure among Reproductive Age HIV-Infected Women in an Urban Clinic. *Infect Dis Obstet Gynecol*. 2016;2016:8048457. doi: 10.1155/2016/8048457. Epub 2016 May 26. PMID:27313441
25. Sankapal S, Gupta P, Ratner D, Ding M, Shen C, Sanyal A, Stolz D, **Cu-Uvin S**, **Ramratnam B**, Chen Y. HIV Exposure to the Epithelia in Ectocervical and Colon Tissues Induces Inflammatory Cytokines Without Tight Junction Disruption. *AIDS Res Hum Retroviruses*. 2016 Jun 16. [Epub ahead of print] PMID:2715393
26. Jais M, Younes N, Chapman S, **Cu-Uvin S**, Ghosh M. *Am J Obstet Gynecol*. Reduced levels of genital tract immune biomarkers in postmenopausal women: implications for HIV acquisition. 2016 Sep;215(3):324.e1-324.e10. doi: 10.1016/j.ajog.2016.03.041. Epub 2016 Mar 26. PMID:27026477
27. Sam SS, Kurpewski JR, **Cu-Uvin S**, Caliendo AM. Evaluation of Performance Characteristics of the Aptima HIV-1 Quant Dx Assay for Detection and Quantitation of Human Immunodeficiency Virus Type 1 in Plasma and Cervicovaginal Lavage Samples. *J Clin Microbiol*. 2016 Apr;54(4):1036-41. doi: 10.1128/JCM.03289-15. Epub 2016 Feb 3. PMID:26842702
28. Dufour AB, Shaffer ML, **D'Agata EMC**, Habtermariam D, Mitchell SL. Survival after suspected urinary tract infections in advanced dementia. *J Am Geriatr Soc*. 2015;63:2472-7. PMID:26613981
29. Snyder G, Patel PR, Kallen AJ, Strom JA, Tucker JK, **D'Agata EMC**. Factors associated with the receipt of antimicrobials among chronic hemodialysis patients. *Am J Infect Control*. 2016 (in press)

30. Wares JR, Lawson B, Shemin D, **D'Agata EMC**. Evaluating infection prevention strategies in out-patient dialysis units using agent-based modeling. *PLOS One*. 2016 19;11(5):e0153820. PMID:27195984
31. Araos, R, Tai AK, Snyder GM, Blaser MJ, **D'Agata EMC**. The protective role of *Lactobacillus* spp. Against Colonization with Multidrug-Resistant Organisms. *Clin Infect Dis*. 2016; 63:937-43. PMID:27358350
32. Shaffer M, **D'Agata EMC**, Habtemariam D, Mitchell SL. Examining the relationship between multidrug-resistant organism acquisition and exposure to antimicrobials in the long-term care population. *Ann Epidemiol*. 2016 (*in press*)
33. Jung DS / **Farmakiotis D** (equal contribution), Yiang J, Tarrand JJ, Kontoyiannis DP. Uncommon *Candida* species fungemia in cancer patients, Houston, Texas, USA. *Emerg Infect Dis*. 2015; 21(11): 1942-50. PMID: 26488845. **Selected for CME activity**
34. Kubiak DW, **Farmakiotis D**, Arons V, Hollins R, Rostas S, Weiser L, Baden LR, Marty FM, Koo S. Utility of in-house fluconazole susceptibility testing in the treatment of candidemia. *Diagn Microbiol Infect Dis*. 2016; 84(3): 223-6. PMID: 26763713.
35. **Farmakiotis D**, Liakos A, Miller MB, Krane JF, Baden LR, Hammond SP. An avid imitator. *J Clin Med Res*. 2016; 8(3): 257-9. PMID: 26858802.
36. Tan X, Zhu S, Yan D, Chen Y, Chen R, Zou J, Yan J, Zhang X, **Farmakiotis D**, **Mylonakis E**. *Candida* spp. airway colonization: A potential risk factor for *Acinetobacter baumannii* ventilator-associated pneumonia. *Med Mycol*. 2016; 54(6): 557-66. PMID: 27001670.
37. Tan X, Zhu S, Chen R, Wang H, Yan D, Zhang X, **Farmakiotis D**, **Mylonakis E**. *Candida albicans* airway colonization facilitates subsequent *Acinetobacter baumannii* pneumonia in a rat model. *Antimicrob Agents Chemother*. 2016; 60(6): 3348-54. PMID: 27001817.
38. Healey KR, Zhao Y, Perez WB, Lockhart SR, Sobel JD, **Farmakiotis D**, Kontoyiannis DP, Sanglard D, Taj-Aldeen SJ, Alexander BD, Jimenez Ortigosa C, Shor E, Perlin DS. Prevalent mutator genotype identified in fungal pathogen *Candida glabrata* promotes multi-drug resistance. *Nat Commun*. 2016; 7: 11128. PMID: 27020939. **Ranked among the top 10 papers in medical mycology at ASM Microbe 2016**
39. **Farmakiotis D**, Zeluff B. Images in clinical medicine. Metronidazole-associated encephalopathy. *N Eng J Med*. 2016; 374(15): 1465. PMID: 27074069.
40. Stempel J, **Farmakiotis D**, Tarrand JJ, Kontoyiannis DP. Time-to-blood culture positivity and central venous catheter-related *Candida glabrata* fungemia in cancer patients. *Diagn Microbiol Infect Dis*. 2016; 85(3): 391-3. PMID: 27133559.

41. **Reece R**, Norman B, Kwara A, **Flanigan TP**, **Rana A**. Retention to Care of HIV-Positive Postpartum Females in Kumasi, Ghana. (2015) *J Int Assoc Provid AIDS Care*. Aug 28. Pii: 2325957415603507. PMID: 26319433
42. Monteiro JF, Escudero DJ, Weinreb C, **Flanigan TP**, Galea S, Friedman SR, Marshall DB. Understanding the effects of different HIV transmission models in individual-based microsimulation of HIV epidemic dynamics in people who inject drugs. (2016) *Epidemiol Infect*. Jun; 144(8):1683-700. PMID: 26753627
43. Costello J, Carpentier M, Sliney A, MacLeod C, Young K, **Flanigan TP**. Evaluation of a Nurse-Initiated Routine HIV Testing Pilot on a Medical-Surgical Unit. (2016) *Medsurg Nurs*. Jan-Feb; 25(1):36-43. PMID: 27044127
44. Kwakwa HA, Bessias S, Sturgis D, Mvula N, Wahome R, Coyle C, **Flanigan TP**. Attitudes toward HIV pre-exposure prophylaxis in the United States Urban Clinic Population. (2016) *AIDS Behav*. Jul; 20(7): 1443-50. PMID: 27115399
45. Kwakwa HA, Wahome R, Goines DS, Jabateh V, Green A, Bessias S, **Flanigan TP**. Engaging African and Caribbean Immigrants in HIV testing and care in a large US city: Lessons learned from the African Diaspora Health Initiative. (2016) *J Immigr Minor Health*. May 19. [Epub ahead of print]. PMID: 27198156
46. Singini I, Campbell TB, Smeaton LM, Kumarasamy N, La Rosa A, Taejareonkul S, Safren SA, **Flanigan TP**, Hakim JG, Hughes MD: ACTG 5175 / PEARLS Study Team. Predictors of late Virologic failure after initial successful suppression of HIV replication on Efavirenz-based antiretroviral therapy. (2016) *HIV Clin Trials*. Jul 29:1-8. PMID: 27472067
47. Rajamuthia R, Jayamani E, Majed H, Conery AL, Kim W, Kwon B, **Fuchs BB**, Kelso MJ, Ausubel FM, **Mylonakis E**. Antibacterial properties of 3-(phenylsulfonyl)-2-pyrazinecarbonitrile. *Bioorg Med Chem Lett*. 2015; 25(22):5203-7.
48. Johnston T, Hendricks GL, Shen S, Chen RF, Kwon B, Kelso MJ, Kim W, **Fuchs BB**, **Mylonakis E**. Raf-kinase inhibitor GW5074 shows antibacterial activity against methicillin-resistant *Staphylococcus aureus* and potentiates the activity of gentamicin. *Future Medicinal Chemistry*. 2016; (In press).
49. **Fuchs BB**, Rajamuthiah R, Souza AC, Eatemadpour S, Rossini R, Santos DA, Junquiera JC, Rice LB, **Mylonakis E**. Inhibition of bacterial and fungal pathogens by the orphaned drug auranofin. *Future Medicinal Chemistry*. 2016; 8(2):117-32.

50. Kim W, Fricke N, Conery AL, **Fuchs BB**, Rajamuthiah R, Jayamani E, Vlahovska PM, Ausubel FM, **Mylonakis E**. NH125 kills methicillin-resistant *Staphylococcus aureus* persists by lipid bilayer disruption. *Future Med Chem*. 2016;8(3):257-69. PMID: 26910612
51. Morton JB, Curzake DJ, Morrill HJ, Parente DM, **Gaitanis MM**, LaPlante KL. Communication With Providers Improves Acceptance of Antimicrobial Stewardship Interventions. *Infect Control Hosp Epidemiol*. 2016 Jun;37(6):740-2. doi: 10.1017/ice.2016.90. No abstract available. PMID: 27198608
52. Morrill HJ, Caffrey AR, **Gaitanis MM**, LaPlante KL. Impact of a Prospective Audit and Feedback Antimicrobial Stewardship Program at a Veterans Affairs Medical Center: A Six-Point Assessment. *PLoS One*. 2016 Mar 15;11(3):e0150795. doi: 10.1371/journal.pone.0150795. eCollection 2016. PMID: 26978263
53. Timothy Archampong Lartey Margaret, Sagoe Kwamena, Obo-Akwa Adjoa, Kenu Ernest, **Gillani FS**, Yang Hongmei, Boamah Isaac, **Flanigan TP**, Kwara Awewura. Proportion and Factors Associated with Hepatitis B Viremia in Antiretroviral Treatment Naïve and Experienced HIV Co-infected Patients, (2016) *BMC Infectious Diseases*. 16:14. DOI: 10.1186/s12879-016-1342-4, PMCID: PMC4710995.
54. RA Oyomopito, YJ Chen, S Sungkanuparph, **Kantor R**, T Merati, WC Yam, T Sirisanthana, PCK Li, P Kantipong, P Phanuphak, CKC Lee, A Kamarulzaman, R Ditangco, SW Huang, AH Sohn, M Law, YMA Chen, on behalf of the TREAT Asia Studies to Evaluate Resistance (TASER). Risk group characteristics and viral transmission clusters in South-East Asian patients infected with HIV-1 circulating recombinant form (CRF)01_AE and subtype B. *Kaohsiung Journal of Medical Sciences*. 2015;31:445-53. PMID 26362956.
55. L Zhang, J Wang, M Coetzer, S Angione, A Tripathi, **Kantor R**. One step Ligation on RNA Amplification for the Detection of Point Mutations. *J Mol Diagn*. 2015;17:679-88. PMCID 4630173.
56. SY Rhee, MR Jordan, E Raizes, A Chua, N Parkin, **Kantor R**, GU Van Zyl, I Mukui, MC Hosseinipour, L Frenkel, N Ndemi, RL Hamers, TF Rinke de Wit, CL Wallis, RK Gupta, J Fokam, C Zeh, JM Schapiro, S Carmona, D Katzenstein, M Tang, AF Aghokeng, T De Oliveira, AMJ Wensing, J Gallant, MA Wainberg, DD Richman, JE Fitzgibbon, M Schito, S Bertagnolio, C Yang, RW Shafer. HIV-1 Drug Resistance Mutations: Potential Application for Point-of-Care Genotypic Testing. *PLOS One*. 2015;10:e0145772. PMID 26717411.
57. KK Tee, **Kantor R**, S Sungkanuparph, Y Takebe, PL MBBS, R Ditangco, P Phanuphak, T Sirisanthana, B Sim, W Ratanasuwan, P Kantipong, A Kamarulzaman, on behalf of the TREAT Asia Studies to Evaluate Resistance – Monitoring (TASER-M) Database.

Transmission networks of HIV-1 among men who have sex with men in east and southeast Asia. *Journal of AIDS*. 2015;70:e28-30. PMID 4556551.

58. A Huang, DA Katzenstein, S Saravanan, Y Wu, S Sirivichayakul, N Kumarasamy, F Zhang, P Phanuphak, **Kantor K**. Global Comparison of Drug Resistance Mutations After First-Line Antiretroviral Therapy Across Human Immunodeficiency Virus-1 Subtypes. *Open Forum Infect Dis*. 2015 Nov 3;3(2):ofv158. doi: 10.1093/ofid/ofv158. eCollection 2016 Apr. PMID: 27419147
59. J Gregson, M Tang, N Ndembu, RL Hamers, SY Rhee, VC Marconi, L Diero, K Brooks, K Theys, TF Rinke de Wit, M Arruda, F Garcia, S Monge, HF Günthard, CJ Hoffmann, PJ Kanki, N Kumarasamy, B Kerschberger, O Mor, C Charpentier, E Todesco, C Rokx, L Gras, EK Halvas, H Sunpath, D Di Carlo, A Antinori, M Andreoni, A Latini, C Mussini, A Aghokeng, A Sonnerborg, U Neogi, WJ Fessel, S Agolory, C Yang, JL Blanco, JM Juma, E Smit, D Schmidt, C Watera, J Asio, W Kirungi, A Tostevin, T El-Hay, N Clumeck, D Goedhals, C van Vuuren, PA Bester, C Sabin, I Mukui, MM Santoro, CF Perno, G Hunt, L Morris, R Camacho, T de Oliveira, D Pillay, E Schuler, A Murakami-Ogasawara, G Reyes-Terán, K Romero, S Avila-Rios, S Sirivichayakul, K Ruxrungtham, S Mekprasan, D Dunn, P Kaleebu, E Raizes, **Kantor R**, RW Shafer, RK Gupta. Global epidemiology of drug resistance following failure of WHO recommended first line regimens for adult HIV-1 infection – a multi-centre retrospective cohort study. *Lancet Infect Dis*. 2016;16: 565–75.
60. E Dufort, W Nyandiko, A DeLong, K Wools-Kaloustian, S Ayaya, J Harwell, **Kantor R**. Misclassification of Treatment Failure Using Immunologic and Clinical Monitoring in HIV Infected Children and Adolescents in Western Kenya. *J Pediatric Infect Dis Soc*. 2016 April 29 [Epub ahead of print].
61. Jin X, Morgan C, Yu X, DeRosa S, Tomaras GD, Montefiori DA, et al. Multiple factors affect immunogenicity of DNA plasmid HIV vaccines in human clinical trials. *Vaccine*. 33(20):2347-2353, 2015. PMID4433533 (**Michelle A. Lally**, Principal Investigator for HVTN 044, HVTN 063, and HVTN 204, Brown/Miriam HIV Vaccine Clinical Trial Site.)
62. Mullins TL, Zimet G, **Lally M**, Kahn JA, and the Adolescent Medicine Trials Network for HIV/AIDS Interventions. Adolescent HIV Care Providers' Attitudes toward the Use of Oral Pre-Exposure Prophylaxis (PrEP) in Youth. *AIDS Patient Care and STDs*. July 2016, 30(7):339-348. doi:10.1089/apc.2016.0048. PMID27410497 PMC4948218
63. Hushie M, Omenyo CN, van den Berg JJ, **Lally M**. State-civil society partnerships for HIV/AIDS treatment and prevention in Ghana: exploring factors associated with successes and challenges. *BMC Health Services Research*. 16(1):332, 2016. PMID 27484178 PMC46969658
64. Savel C, Mierzwa S, Gorbach P, Souidi S, **Lally M**, et al, Adolescent Trials Network for HIV/AIDS Interventions. Avatar Web-Based Self-Report Survey System Technology for Public Health Research: Technical Outcome Results and Lessons Learned. Online *J*

Public Health Informatics. 8(2):e189, 2016.

65. Hosek S, Rudy B, Landovitz R, Kapogiannis B, Rutledge B, Liu N, Brothers J, Mulligan K, **Lally M**, Zimet G, Mayer K, Rooney J, Wilson CM and the Adolescent Medicine Trials Network for HIV/AIDS Interventions. An HIV Pre-Exposure Prophylaxis (PrEP) Demonstration Project and Safety Study for Young MSM(ATN 110). *J Acquir Immune Defic Syndr*. [Epub 9/13/16] PMID27632233
66. Brown V, **Lally M**. Reducing Inappropriate H. Pylori Antibody Testing: A Quality Improvement Initiative Quality in Primary. *Quality in Primary Care*. Accepted for publication on 8/26/16.
67. **Li M**, Tucker LD, Asara JM, Cheruiyot C, Lu H, W ZJ, Newstein MC, Dooner MS, Friedman J, **Lally MA**, **Ramratnam B**. Stem-loop binding protein is a multifaceted cellular regulator of HIV-1. *J Clin Invest*. 126(8):3117-29, 2016. PMID27454292 PMC4966322
68. **Li M**, and **Ramratnam B**. Proteomic characterization of exosomes from HIV-1 infected cells. *Methods Mol Biol*. 2016;1354:311-26. PMID: 26714721.
69. **Opal SM**. Is genomic medicine finally coming of age for the diagnosis of pneumonia? *Am J Respir Crit Care Med*. 2015 Oct 1;192(7):773-4. doi: 10.1164/rccm.201507-1340ED. No abstract available. PMID: 26426779
70. **Opal SM**, Ellis JL, Suri V, Freudenberg JM, Vlasuk GP, Li Y, Chahin AB, Palardy JE, Parejo N, Yamamoto M, Chahin A, Kessimian N. Sirt1 Activation Markedly Alters Transcription Profiles and Improves Outcome in Experimental Sepsis. *Shock*. 2015 Nov 16. [Epub ahead of print] PMID: 26641650
71. Walley KR, Francis GA, **Opal SM**, Stein EA, Russell JA, Boyd JH The Central Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Septic Pathogen Lipid Transport and Clearance. *Am J Respir Crit Care Med*. 2015 Dec 1;192(11):1275-86. doi: 0.1164/rccm.201505-0876CI. PMID: 26252194
72. Giamarellos-Bourboulis EJ, **Opal SM**. The role of genetics and antibodies in sepsis. *Ann Transl Med*. 2016;4(17):328. PMID: 27713886
73. North JR, Takenaka S, Rozek A, Kielczewska A, **Opal SM**, Morici LA, Finlay BB, Schaber CJ, Straube R, Donini O. A novel approach for emerging and antibiotic resistant infections: Innate defense regulators as an agnostic therapy. *J Biotechnol*. 2016 May 20;226:24-34. doi: .1016/j.jbiotec.2016.03.032. Epub 2016 Mar 23. PMID: 27015977
74. Long-Term Quality of Life Among Survivors of Severe Sepsis: Analyses of Two International Trials. Yende S, Austin S, Rhodes A, Finfer S, **Opal SM**, Thompson T, Bozza FA, LaRosa SP, Ranieri VM, Angus DC. *Crit Care Med*. 2016 Aug;44(8):1461-7. doi: .1097/CCM.0000000000001658. PMID: 26992066

75. Immunosuppression and Secondary Infection in Sepsis: Part, Not All, of the Story. Angus DC, **Opal SM**. *JAMA*. 2016 Apr 12;315(14):1457-9. doi: 10.1001/jama.2016.2762. No abstract available. PMID: 26975243
76. **Opal SM**, Ellis JL, Suri V, Freudenberg JM, Vlasuk GP, Li Y, **Chahin AB**, Palardy JE, Parejo N, Yamamoto M, Chahin A, Kessimian N. PHARMACOLOGICAL SIRT1 ACTIVATION IMPROVES MORTALITY AND MARKEDLY ALTERS TRANSCRIPTIONAL PROFILES THAT ACCOMPANY EXPERIMENTAL SEPSIS. *Shock*. 2016 Apr;45(4):411-8. doi: 10.1097/SHK.0000000000000528. PMID: 26974318
77. Fedson DS, Jacobson JR, Rordam OM, **Opal SM**. Reply to "Generic Statins and Angiotensin Receptor Blockers: Are They Really Useful in Ebola?". *MBio*. 2016 Feb 23;7(1):e00094-16. doi: 10.1128/mBio.00094-16. No abstract available. PMID: 26908575
78. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, **Opal SM**, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA*. 2016 Feb 23;315(8):801-10. doi: 10.1001/jama.2016.0287. PMID: 26903338
79. Isolating Influenza RNA from Clinical Samples Using Microfluidic Oil-Water Interfaces. Cui FR, Wang J, **Opal SM**, Tripathi A. *PLoS One*. 2016 Feb 17;11(2):e0149522. doi: 10.1371/journal.pone.0149522. eCollection 2016. PMID: 26886007
80. Chawla LS, Fink M, Goldstein SL, **Opal SM**, Gómez A, Murray P, Gómez H, Kellum JA. THE EPITHELIUM AS A TARGET IN SEPSIS.; ADQI XIV Workgroup. *Shock*. 2016 Mar;45(3):249-58. doi: 10.1097/SHK.0000000000000518. PMID: 26863125
81. Shakoory B, Carcillo JA, Chatham WW, Amdur RL, Zhao H, Dinarello CA, Cron RQ, **Opal SM**. Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial. *Crit Care Med*. 2016 Feb;44(2):275-81. doi: 10.1097/CCM.0000000000001402. PMID: 26584195
82. Angione S, Croote D, Leung J, **Mermel L**, Tripathi A. Single fluorophore melting curve analysis for detection of hypervirulent *Clostridium difficile*. *J Med Micro*. 65:62-70, 2016.
83. Luther MK, **Mermel LA**, LaPlante KL. Comparison of telavancin and vancomycin lock solutions in eradication of biofilm-producing staphylococci and enterococci from central venous catheters. *Am J Health-Syst Pharm*. 73:315-21, 2016.
84. Morrill HJ, **Mermel LA**, Baier RR, Alexander-Scott N, Dosa D, Kavoosifar S, **Reece R**, LaPlante KL. Antimicrobial stewardship in Rhode Island long-term care facilities:

- Current standings and future opportunities. *Infect Control Hosp Epidemiol.* 37:979-82, 2016.
85. Pages J, Hazera P, Mégarbane B, du Cheyron D, Thuong M, Dutheil J-J, Valette X, Fournel F, **Mermel LA**, Mira J-P, Daubin C, Parienti J-J, for the 3SITES Study Group. Comparison of alcoholic chlorhexidine and povidone-iodine cutaneous antiseptics for the prevention of central venous catheter-related infection: a cohort and quasi-experimental multi-center study. *Intensive Care Med.* 42:1418-1426, 2016.
 86. Ravishankar S, Chapin K, Alexander-Scott N, Wills H, Merritt C, Jacobson M, Kleris R, Alhinai Z, Sediva I, Muratore C, **Mermel L**, Mangray S. Enterovirus D68 and Panton-Valentine Leukocidin positive Staphylococcus aureus respiratory co-infection with fatal outcome. *Pediatr Dev Pathol.* 19:80-85, 2016.
 87. Ward NS, Hughes BL, **Mermel LA**. Adult Enterovirus D68 infection. *Am J Crit Care.* 25:178-180, 2016.
 88. Parienti JJ, du Cheyron D, **Mermel LA**; 3SITES Study Group. Complications of Central Venous Catheterization. *N Engl J Med.* 374:1491-1492, 2016.
 89. Alang N, Glavis-Bloom J, Alexander-Scott N, **Mermel LA**, **Mileno MD**. Surveillance of travel-related mosquito-borne illness in Rhode Island. *Med Health RI.* 99:23-24, 2016.
 90. Govindan JA, Jayamani E, Zhang X, Breen P, Larkins-Ford J, **Mylonakis E**, Ruvkun G. Lipid signalling couples translational surveillance to systemic detoxification in *Caenorhabditis elegans*. *Nature Cell Biol.* 2015;17(10):1294-303. PMID: 26322678
 91. Dolla NK, Chen C, Larkins-Ford J, Rajamuthiah R, Jagadeesan S, Conery AL, Ausubel FM, **Mylonakis E**, Bremner JB, Lewis K, Kelso MJ. On the mechanism of berberine-INF55 (5-Nitro-2-Phenylindole) hybrid antibacterials. *Aust J Chem.* 2015;67:1471-1480. PMID: 26806960
 92. Karanika S, Paudel S, Zervou FN, Grigoras C, Zacharioudakis IM, **Mylonakis E**. Prevalence and clinical outcomes of *Clostridium difficile* infection in the intensive care unit: A systematic review and meta-analysis. *Open Forum Infect Dis.* 2015;3(1):ofv186. PMID: 26788544
 93. Zervou FN, Zacharioudakis IM, Pliakos EE, Grigoras CA, Ziakas PD, **Mylonakis E**. Adaptation of cost analysis studies in practice guidelines. *Medicine[Baltimore]* 2015;94(52):e2365. PMID: 26717377
 94. Muhammed M, Arvanitis M, **Mylonakis E**. Whole animal HTS of small molecules for antifungal compounds. *Expert Opin Drug Discov.* 2016;11(2):117-84. PMID: 26593386

95. Liu Y, Huang X, Yi X, He Y, **Mylonakis E**, Xi L. Detection of *Talaromyces marneffe* from fresh tissue of an inhalational murine pulmonary model using nested. PCR. *PLoS ONE*. 2016;11(2):e0149634. PMID: 26886887
96. **Mylonakis E**, Podsiadlowski L, Muhammed M, Vilcinskas. Diversity, evolution and medical applications of insect antimicrobial peptides. *Philos Trans R Soc Lond B Biol Sci*. 2016;371(1695). PMID: 27160593
97. Karanika S, Karantanos T, Arvanitis M, Grigoras C, **Mylonakis E**. Fecal colonization with extended-spectrum beta-lactamase-producing *Enterobacteriaceae* and risk factors among healthy individuals: A systematic review and meta-analysis. *Clin Infect Dis*. 2016;63(3):310-8. PMID: 27143671
98. Arvanitis M, Li G, Li D, Cotnoir D, Ganley-Leal L, Carney DW, Sello JK, **Mylonakis E**. A conformationally constrained cyclic acyldepsipeptide is highly effective in mice infected with methicillin-susceptible and -resistant *Staphylococcus aureus*. *PLoS ONE*. 2016;11(4):e0153912. PMID: 27101010
99. Karanika S, Kinamon T, Grigoras C, **Mylonakis E**. Colonization with methicillin-resistant *Staphylococcus aureus* and risk for infection among asymptomatic athletes: a systematic review and meta-analysis. *Clin Infect Dis*. 2016;63(2):195-204. PMID: 27090988
100. Karanika S, Paudel S, Grigoras C, Kalbasi A, **Mylonakis E**. Clinical and economic outcomes from the implementation of hospital-based antimicrobial stewardship programs: A systematic review and meta-analysis. *Antimicrob Agents Chemother*. 2016;60(8):4840-52. PMID: 27246783
101. Grigoras C, Zervou F, Zacharioudakis IM, **Mylonakis E**. Isolation of *C. difficile* carriers alone and as part of a bundle approach for the prevention of *Clostridium difficile* infection (CDI): A mathematical model based on clinical study data. *PLoS ONE*. 2016;11(6):e0156577. PMID: 27258068
102. Flokas M, Alevizakos M, **Mylonakis E**. Prevalence of ESBL-producing *Enterobacteriaceae* in paediatric urinary tract infections: A systematic review and meta-analysis. *J Infection*. 2016;Jul 28. Pii:S0163-4453(16)30178-5. (Epub ahead of print) PMID: 27475789
103. Ziakas PD, Joyce N, Zacharioudakis IM, Zervou FN, Besdine RW, Mor V, **Mylonakis E**. Prevalence and impact of *Clostridium difficile* infection in elderly residents of long-term care facilities, 2011: A nationwide study. *Medicine (Baltimore)*. 2016 Aug;95(31):e4187. PMID: 27495022

104. Alevizakos M, Karanika S, Detsis M, **Mylonakis E**. Colonization with ESBL-producing Enterobacteriaceae and risk for infection among patients with solid or hematologic malignancy: a systematic review and meta-analysis. *Int J Antimicrob Agents*. (in press).
105. Hendricks G, **Mylonakis E**. Expanding the nematode model system: the molecular basis of inflammation and infection recovery in *C. elegans*. *Virulence* (in press).
106. Avci P, Freire F, Banvolgyi A, **Mylonakis E**, Wikonkal NM, Hamblin MR. Sodium ascorbate kills *Candida albicans* in vitro via iron-catalyzed Fenton reaction: importance of oxygenation and metabolism. *Future Microbiol.* (in press).
107. Timbrook TT, Morton JB, McConeghy KW, Caffrey AR, **Mylonakis E**, LaPlante KL. The Effect of molecular rapid diagnostic testing on clinical outcomes in bloodstream infections: a systematic review and meta-analysis. *Clin Infect Dis.* (in press).
108. Coleman JJ, Komura T, Munro J, Wu P, Busanelli RR, Koehler AN, Thomas M, Wagner FF, Holson EB, **Mylonakis E**. The immunomodulatory activity of CAPE in *Caenorhabditis elegans* is mediated by the CED-10 (Rac-1)/PAK-1 pathway. *Future Med Chem.* (in press).
109. Grounta A, Harizanis P, **Mylonakis E**, Nychas EGJ, Panagou EZ. Investigating the effect of different treatments with lactic acid bacteria on the fate of *Listeria monocytogenes* and *Staphylococcus aureus* infection in *Galleria mellonella* larvae. *PLoS ONE*. (in press).
110. Maged M, Arvanitis M, **Mylonakis E**. High-throughput screening of small molecules for treating Candida infections. *Expert Opin Drug Discov.* (in press).
111. Zervou FN, Zacharioudakis IM, Kurpewski J, **Mylonakis E**. T2 Magnetic resonance for fungal diagnosis. *Methods Mol Biol.* (in press).
112. Alevizakos M, Detsis M, Grigoras CA, Machan JT, **Mylonakis E**. The impact of shortages on medication prices: Implications for shortage prevention. *Drugs.* (in press).
113. Uyeki TM, Erickson BR, Brown S, McElroy AK, Cannon D, Gibbons A, Sealy T, Kainulainen MH, Schuh AJ, Kraft CS, Mehta AK, Lyon GM 3rd, Varkey JB, Ribner BS, Ellison RT 3rd, Carmody E, **Nau GJ**, Spiropoulou C, Nichol ST, Ströher U. Ebola Virus Persistence in Semen of Male Survivors. *Clin Infect Dis.* 2016 Jun 15;62(12):1552-5.
114. **Noska A**, Mohan A, Wakeman S, **Rich J**, Boutwell A. Managing Opioid Use Disorder in the General Hospital: A Case-Based Review Clarifying Methadone Regulation for Acute Care Settings. *J Addict Behav Ther Rehabil.* 2015;4(2). pii: 1000138. PMID: 26258153
115. **Noska A**, Roberts M, Stein L, Sufrin C, **Beckwith C**, **Rich J**, Dauria E, Clarke J. History of sex exchange in women with a history of incarceration. *J of Health Care for the Poor and Underserved.* 2016;27(2A):149-62. PMID: 27133516

116. Wu, C, **Noska A**. An Intrauterine device infection causing concomitant streptococcal toxic shock syndrome and pelvic abscess with *Actinomyces odontolyticus* bacteremia. *BMJ Case Reports*. 2016; [online] doi:10.1136/bcr-2015-213236.
117. Zaller ND, Patry EJ, Bazerman LB, **Noska A**, Kuo I, Kurth A, **Beckwith CG**. A Pilot Study of Rapid Hepatitis C Testing in Probation and Parole Populations in Rhode Island. *J Health Care Poor Underserved*. 2016; 27(2A):214-23.PMID: 27133520.
118. Hughes BL, Dutt R, Raker C, Barthelemy M, Rossoll RM, **Ramratnam B**, Wira CR, **Cu-Uvin S**. The impact of pregnancy on anti-HIV activity of cervicovaginal secretions. *Am J Obstet Gynecol*. 2016 Jul 5. pii: S0002-9378(16)30402-1. doi: 10.1016/j.ajog.2016.06.057. [Epub ahead of print] PMID: 27393267
119. Monnig MA, Kahler CW, Cioe PA, Tucker L, Monti PM, Mayer KH, **Ramratnam B**. Alcohol use predicts elevation in inflammatory marker soluble CD14 in men living with HIV. *AIDS Care*. 2016 Nov;28(11):1434-40. doi: 10.1080/09540121.2016.1189497. Epub 2016 May 30. PMID: 27242060
120. Ahsan N, Rao RS, Gruppuso PA, **Ramratnam B**, Salomon AR Targeted proteomics: Current status and future perspectives for quantification of food allergens. *J Proteomics*. 2016 Jun 30;143:15-23. doi: 10.1016/j.jprot.2016.04.018. Epub 2016 Apr 22. Review. PMID: 27113134
121. Kojic EM, **Rana AI**, **Cu-Uvin S**. Human papillomavirus vaccination in HIV-infected women: need for increased coverage. *Expert Rev Vaccines*. 2016 Jan; 15(1):105-117. PMID:26599305
122. **Rana AI**, van den Berg JJ, Lamy E, **Beckwith C**. Using a Mobile Health Intervention to Support HIV Treatment Adherence and Retention among Patients at Risk for Disengaging with Care. *AIDS Patient Care and STDs*. 2016 Apr; 30(4):178-84. PMID: 27028183
123. Kumar N, **Reece R**, Norman B, Kwara A, **Flanigan TP**, **Rana AI**. Delayed entry to care by men with HIV infection in Kumasi, Ghana. (2015) *Pan African md Journal*. Oct 7;22 :107. PMID: 26848354. PMCID: PMC4732647
124. Morrill HJ, Mermel LA, Baier RR, Alexander-Scott N, Dosa D, Kavoosifar S, **Reece R**, LaPlante KL. Antimicrobial Stewardship in Rhode Island Long-Term Care Facilities: Current Standings and Future opportunities. (2016) *Infect Control Hosp Epidemiol*. Aug;37(8):979-82. PMID: 27185014

125. Nguyen JT, **Rich JD**, Brockmann BW, Vohr F, Spaulding A, Montague BT. A budget impact analysis of newly available hepatitis C therapeutics and the financial burden on a state correctional system. *J Urban Health*. 92(4): 635-49, 2015. PMID: PMC4524840
126. Wakeman SE, **Rich JD**. Addiction treatment within U.S. correctional facilities: bridging the gap between current practice and evidence-based care. *J Addict Dis*. 34(2-3):220-5, 2015. PMID: 26076211
127. Montague BT, Rosen DL, Sammartino C, Costa M, Gutman R, Solomon L, **Rich JD**. Systematic assessment of linkage to care for persons with HIV released from corrections facilities using existing datasets. *AIDS Pt Care STDs*. 30(2):84-92, 2016. PMID: PMC4753628
128. Christopher PP, Stein MD, Johnson JE, **Rich JD**, Friedmann PD, Clarke J, Lidz CW. Exploitation of prisoners in clinical research: perceptions of study participants. *IRB: Ethics & Hum Res*. 38(1):7-12, 2016. PMID: PMC4793400
129. Christopher PP, Stein MD, Springer SA, **Rich JD**, Johnson JE, Lidz CW. An exploratory study of therapeutic misconception among incarcerated clinical trial participants. *AJOB Empirical Bioethics* Posted Online June 24, 2015, doi 10.1080/23294515.2015.1058303, Vol 7(1):24-30, 2016. PMID: PMC4687735
130. Wakeman SE, **Rich JD**. Barriers to post-acute care for patients on opioid agonist therapy; an example of systematic stigmatization of addiction. *J Gen Int Med*. (accepted for publication, 2016). PMID: 27393486
131. **Rich JD**, Beckwith CG, Macmadu A, Marshall BDL, Brinkley-Rubinstein L, Amon JJ, Milloy M-J, King MRF, Sanchez J, Atwoli L, Altice FL. Clinical care of incarcerated people with HIV, viral hepatitis, or tuberculosis. *Lancet* (published online July 14, 2016, [http://dx.doi.org/10.1016/S0140-6736\(16\)30379-8](http://dx.doi.org/10.1016/S0140-6736(16)30379-8)). NIHMSID: 813269
132. Gordon MS, Restivo L, Carswell SB, Kinlock TW, McKenzie M, **Rich JD**. Factors associated with undergoing rapid HIV testing among individuals on probation or parole. *J Corr Health Care*. (accepted for publication, 2016.)
133. Garcia A, Bachmaha M, Zaller N, **Rybak N**, Vasylev M, Dasho Y, Flanigan T and Sluzhynska M. Lessons Learned: A qualitative study of integrated care for HIV-infected injecting drug users in Lviv, Ukraine. *J of Therapy and Management in HIV Infection*. 2015; 3:1-6.
134. **Rybak N**, Carroll JJ, Bachmaha M, Garcia A, Vasylev M, Flanigan T and Sluzhynska M. HIV testing and entry into HIV care in Lviv, Western Ukraine 2005-2013. *J AIDS Clin Res*. 2015; 6(8): 494-9, doi:10.4172/2155-6113.
135. Stanton CA, Papandonatos GD, Shuter J, Bicki A, Lloyd-Richardson EE, deDios MA, Morrow KM, Makgoeng SB, **Tashima KT**, Niaura RS. Outcomes of a Tailored

- Intervention for Cigarette Smoking Cessation among Latinos living with HIV/AIDS. (2015) *Nicotine Tob Res.* Aug; 17(8):975-82. Doi: 10.1093/ntr/ntv014. PMID: 26180222
136. **Tashima KT**, Mollan KR, Na L, Gandhi RT, Klingman KL, Fichtenbaum CJ, Andrade A, Johnson VA, Eron JJ, Smeaton L, Haubrich RH. Regimen selection in the OPTIONS trial of HIV salvage therapy: drug resistance, prior therapy, and race-ethnicity determine the degree of regimen complexity. (2015) *HIV Clin Trials.* Aug; 16(4):147-56. Doi: 10.1179-1945577115Y.0000000001. Epub 2015 Jul 27. PMID: 26212575
137. Seider TR, Gongvatana A, Woods AJ, Chen H, Porges EC, Cummings T, Correia S, **Tashima K**, Cohen RA. Age exacerbates HIV-associated white matter abnormalities. (2015) *J Neurovirol.* Oct 7. [Epub ahead of print] PMID: 26446690
138. **Tashima KT**, Smeaton LM, Fichtenbaum CJ, Andrade A, Eron JJ, Gandhi RT, Johnson VA, Klingman KL, Ritz J, Hodder S, Santanta JL, Wilkin T Haubrich RH: A5241 Study Team. HIV Salvage Therapy does not require Nucleoside Reverse Transcriptase Inhibitors: A randomized, controlled trial. (2015) *Ann Intern Med.* Nov 24:908-17. doi.10.7326/M15-949. PMID: 26595748
139. Wohl D, Oka S, Clumeck N, Clarke A, Brinson C, Stephens J, **Tashima K**, Arribas JR, Rashbaum B, Cheret A, Brunetta J, Mussini C, Tebas P, Sax PE, Cheng A, Zhong L, Callebaut C, Das M, Fordyce M: GS-US-2,92-01040111 and Study Team. Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide versus Tenofovir Disoproxil Fumarate, each Coformulated with Elvitegravir, Cobisistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results. (2016) *J Acquir Immune Defic Syndr.* May 1;72(1): 58-64. PMID: 26829661
140. Okafor CN, Kelso NE, Bryant V, Burrell LE 2nd, Miguez MJ, Gongvatana A, **Tashima KT**, DelaMonte S, Cook RL, Cohen RA. Body mass index inflammatory biomarkers and neurocognitive impairment in HIV-infected persons. (2016) *Psychol Health Med.* Jun 20; 1-14. [Epub ahead of print]. PMID: 27319430
141. Grebely J, Robaey G, Bruggmann P, Aghemo A, Backmund M, Bruneau J, Byrne J, Dalgard O, Feld JJ, Hellard M, Hickman M, Kautz A, Litwin A, Lloyd AR, Mauss S, Prins M, Swan T, Schaefer M, **Taylor LE**, Dore GJ; International Network for Hepatitis in Substance Users. Recommendations for the management of hepatitis C virus infection among people who inject drugs. *Int J Drug Policy.* 2015 Oct;26(10):1028-38. PMID: 26282715
142. Grebely J, Haire B, **Taylor LE**, Macneill P, Litwin AH, Swan T, Byrne J, Levin J, Bruggmann P, Dore GJ; International Network for Hepatitis in Substance Users. Excluding people who use drugs or alcohol from access to hepatitis C treatments - Is this fair, given the available data? *J Hepatol.* 2015 Oct;63(4):779-82. PMID: 26254264. PMC – In Process

143. Grebely J, Robaey G, Bruggmann P, Aghemo A, Backmund M, Bruneau J, Byrne J, Dalgard O, Feld JJ, Hellard M, Hickman M, Kautz A, Litwin A, Lloyd AR, Mauss S, Prins M, Swan T, Schaefer M, **Taylor LE**, Dore GJ; l'International Network on Hepatitis among Substance Users (Réseau international sur l'hépatite chez les consommateurs de drogues). Recommandations pour la prise en charge de l'infection par le virus de l'hépatite C chez les usagers de drogues par injection. *Int J Drug Policy*. 2015 Nov 28. [Epub ahead of print] PMID: 26847504
144. Grebely J, Dore GJ, Greenwald R, Swan T, Barua S, **Taylor LE**. Hepatitis C Virus Treatment and Persons Who Inject Drugs. *Ann Intern Med*. 2016 Feb 2;164(3):203. PMID: 26829914
145. Mahowald MK, Larney S, Zaller ND, Scharff N, **Taylor LE**, **Beckwith CG**, **Noska A**, **Rich JD**, **Flanigan TP**. Characterizing the Burden of Hepatitis C Infection Among Entrants to Pennsylvania State Prisons, 2004-2012. *J Correct Health Care*. 2016 Jan;22(1): 41-5. PMID: 26672118
146. Soipe AI, Razavi H, Razavi-Shearer D, Galárraga O, **Taylor LE**, Marshall BDL. Chronic hepatitis C virus (HCV) burden in Rhode Island: Modeling treatment scale-up and elimination. *Epidemiology & Infection*. 2016 (Epub ahead of print). DOI: 10.1017/S0950268816001722.
147. Marshall AD, Saeed S, Barrett L, Cooper CL, Treloar C, Bruneau J, Feld JJ, Gallagher L, Klein MB, Krajden M, Shoukry NH, **Taylor LE**, Grebely J, on behalf of the Canadian Network on Hepatitis C (CanHepC). A Review of Restrictions for Reimbursement of Direct-Acting Antiviral Treatment for Hepatitis C Virus Infection in Canada. *CMAJ Open*. Accepted for publication. August 2016.
148. **Taylor LE** and Fierer DS. Treatment of Early Hepatitis C Infection in HIV-infected Men—When to Treat, Whom, and with What? *Curr Treat Options Infect Dis*. Accepted for publication. September 2016.
149. Shah KN, Truntzer JN, **Touzard-Romo F**, Rubin LE. Total Joint Arthroplasty in Patients with Human Immunodeficiency Virus. (2016) *JBJS reviews*. Accepted, in press. January 2016
150. Bloch KC, Bitnun A, Glaser CA, Mailles A, Stahl JP, **Tunkel AR**, Venkatesan A. Reply to Jackson. *Clin Infect Dis*. 2015;61:293-294.
151. **Tunkel AR**. Biology of infectious disease. In: The Merck Manual Consumer Version. Porter RS, ed. www.merckmanuals.com/home. Merck & Co., last updated and published online September 2016.
152. DeLuca M, Gruppuso PA, **Wing EJ**. Successful treatment of Takayasu's arteritis in an HIV positive adult patient with long term follow up. Case Reports in *Internal Medicine* 3(4): 14-17, 2016.

153. **Wing EJ.** Toxoplasmosis: Cats Have It, Humans Get It, but How Much Disease Does It Cause? Editorial Commentary. *Clin Infect Dis.* 63(4):476-477, 2016. PMID27353664
154. Katie M. Becofsky, **Wing EJ**, Rena R. Wing, R Kathryn E. Richards, **Gillani FS**, (2016) Obesity prevalence and related risk of co-morbidities among HIV+ patients attending a New England ambulatory center. *Obesity Science & Practice.* 2: 123–127. DOI: 10.1002/osp4.38.